Finoriq research workspace
ANAVEX LIFE SCIENCES CORP. (AVXL) SEC Filings & Filing Highlights
Anavex Life Sciences Corp. operates as a biopharmaceutical company. Review AVXL SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
- Company
- ANAVEX LIFE SCIENCES CORP. (AVXL)
- Ticker
- AVXL
- Market Cap
- $223.8M
- Latest Price
- $2.415
- Industry
- Biotech & Pharma
ANAVEX LIFE SCIENCES CORP. (AVXL) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ANAVEX LIFE SCIENCES CORP. (AVXL).
| Event | Form | Date |
|---|---|---|
| ANAVEX LIFE SCIENCES CORPOn June 25, 2026, the Board of Directors (the “Board”) of Anavex Life Sciences Corp. (the “Company”) established September 24, 2026, as the... | 8-K8.01 | 2026-06-26 |
| Anavex Life Sciences Receives Expected Nasdaq Delinquency NotificationAnavex Life Sciences Receives Expected Nasdaq Delinquency Notification | 8-K8.01 | 2026-05-22 |
| The Notice has no immediate effect on the listing of the Company’s common stock, which continue...On May 20, 2026, Anavex Life Sciences Corp. (the “Company”) received a delinquency notification letter (the “Notice”) from the Listing Qual... | 8-K3.01 | 2026-05-22 |
| Departure of Chief Operating Officer On May 11, 2026, Felix Lauscher, who had held the title of...Departure of Chief Operating Officer On May 11, 2026, Felix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Scie... | 8-K5.02 | 2026-05-15 |
| Termination of Chief Executive Officer On April 30, 2026, a special committee (the “Special Com...Termination of Chief Executive Officer On April 30, 2026, a special committee (the “Special Committee”) composed of independent directors o... | 8-K5.02 | 2026-05-06 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.